C07C63/06

Aromatic compounds from furanics

Described are methods for preparing phenols, benzene carboxylic acids, esters and anhydrides thereof from furanic compounds by reaction with a dienophile, wherein the furanic compounds are reacted with a hydrazine and/or oxime and then reacted with a dienophile.

Cooling loop with a supercritical fluid system using compressed refrigerant fluid flow with a positive Joule Thomson coefficient

Provided is a chiller and system that may be utilized in a supercritical fluid chromatography method, wherein a non-polar solvent may replace a portion or all of a polar solvent for the purpose of separating or extracting desired sample molecules from a combined sample/solvent stream. The system may reduce the amount of polar solvent necessary for chromatographic separation and/or extraction of desired samples. The system may incorporate a supercritical fluid chiller, a supercritical fluid pressure-equalizing vessel and a supercritical fluid cyclonic separator. The supercritical fluid chiller allows for efficient and consistent pumping of liquid-phase gases employing off-the-shelf HPLC pumps. The pressure equalizing vessel allows the use of off-the-shelf HPLC column cartridges. The system may further incorporate the use of one or more disposable cartridges containing silica gel or other suitable medium. The system may also utilize an open loop cooling circuit using fluids with a positive Joule-Thomson coefficient.

Cooling loop with a supercritical fluid system using compressed refrigerant fluid flow with a positive Joule Thomson coefficient

Provided is a chiller and system that may be utilized in a supercritical fluid chromatography method, wherein a non-polar solvent may replace a portion or all of a polar solvent for the purpose of separating or extracting desired sample molecules from a combined sample/solvent stream. The system may reduce the amount of polar solvent necessary for chromatographic separation and/or extraction of desired samples. The system may incorporate a supercritical fluid chiller, a supercritical fluid pressure-equalizing vessel and a supercritical fluid cyclonic separator. The supercritical fluid chiller allows for efficient and consistent pumping of liquid-phase gases employing off-the-shelf HPLC pumps. The pressure equalizing vessel allows the use of off-the-shelf HPLC column cartridges. The system may further incorporate the use of one or more disposable cartridges containing silica gel or other suitable medium. The system may also utilize an open loop cooling circuit using fluids with a positive Joule-Thomson coefficient.

Iron sulfide dissolver

An aqueous iron sulfide dissolver including zinc, chromium, a methoxybenzoic acid, formic acid, acetic acid, and hydrochloric acid. The iron sulfide dissolver is made by combining these components, and dissolves compounds including iron sulfide upon contact. Evolved hydrogen sulfide reacts with the methoxybenzoic acid to yield solubilized methanethiol as an intermediate product, which is further oxidized to yield dissolved dimethyl disulfide.

Iron sulfide dissolver

An aqueous iron sulfide dissolver including zinc, chromium, a methoxybenzoic acid, formic acid, acetic acid, and hydrochloric acid. The iron sulfide dissolver is made by combining these components, and dissolves compounds including iron sulfide upon contact. Evolved hydrogen sulfide reacts with the methoxybenzoic acid to yield solubilized methanethiol as an intermediate product, which is further oxidized to yield dissolved dimethyl disulfide.

Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives

The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.

Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives

The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.

Method to prepare phenolics from biomass

The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a phenolic compound; reacting the phenolic compound further to obtain the final phenolic product.

Method to prepare phenolics from biomass

The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a phenolic compound; reacting the phenolic compound further to obtain the final phenolic product.

FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR

The present application in some embodiments provides a pharmaceutical composition comprising:

##STR00001## and a compounding agent. Further provided herein are methods of making and methods of using the pharmaceutical compositions, for example, in the treatment of cancer.